Novavax Issuance Of Capital Stock vs Cash Flows Other Operating Analysis
NVAX Stock | USD 8.47 0.43 5.35% |
Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Issuance Of Capital Stock and its Cash Flows Other Operating accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Issuance Of Capital Stock vs Cash Flows Other Operating
Issuance Of Capital Stock vs Cash Flows Other Operating Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Issuance Of Capital Stock account and Cash Flows Other Operating. At this time, the significance of the direction appears to have pay attention.
The correlation between Novavax's Issuance Of Capital Stock and Cash Flows Other Operating is -0.95. Overlapping area represents the amount of variation of Issuance Of Capital Stock that can explain the historical movement of Cash Flows Other Operating in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Issuance Of Capital Stock and Cash Flows Other Operating is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Issuance Of Capital Stock of Novavax are associated (or correlated) with its Cash Flows Other Operating. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Flows Other Operating has no effect on the direction of Issuance Of Capital Stock i.e., Novavax's Issuance Of Capital Stock and Cash Flows Other Operating go up and down completely randomly.
Correlation Coefficient | -0.95 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Issuance Of Capital Stock
Cash Flows Other Operating
Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).
Novavax fundamental ratios Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 173.0M | 1.6B | 2.6B | 2.3B | 1.8B | 1.9B | |
Other Current Liab | 19.9M | (327.6M) | 709.8M | 1.5B | 1.3B | 1.3B | |
Total Current Liabilities | 25.8M | 322.0M | 2.4B | 2.5B | 1.6B | 1.7B | |
Total Stockholder Equity | (186.0M) | 627.2M | (351.7M) | (634.1M) | (716.9M) | (681.1M) | |
Property Plant And Equipment Net | 11.4M | 180.0M | 228.7M | 400.5M | 491.0M | 515.5M | |
Net Debt | 243.1M | (231.4M) | (1.1B) | (787.1M) | (339.4M) | (322.5M) | |
Retained Earnings | (1.4B) | (1.9B) | (3.6B) | (4.3B) | (4.8B) | (4.6B) | |
Accounts Payable | 2.9M | 54.3M | 127.1M | 216.5M | 132.6M | 139.2M | |
Cash | 78.8M | 553.4M | 1.5B | 1.3B | 568.5M | 596.9M | |
Non Current Assets Total | 75.7M | 334.3M | 421.6M | 555.3M | 711.5M | 747.0M | |
Non Currrent Assets Other | 7.5M | 13.2M | 56.7M | 28.5M | 88.1M | 92.5M | |
Cash And Short Term Investments | 78.8M | 711.0M | 1.5B | 1.3B | 568.5M | 596.9M | |
Common Stock Shares Outstanding | 24.1M | 57.6M | 74.4M | 78.2M | 100.8M | 105.8M | |
Liabilities And Stockholders Equity | 173.0M | 1.6B | 2.6B | 2.3B | 1.8B | 1.9B | |
Other Current Assets | 93.9M | 441.8M | 176.1M | 247.5M | 236.4M | 248.3M | |
Other Stockholder Equity | 1.3B | 2.5B | 3.3B | 3.6B | 4.1B | 4.3B | |
Total Liab | 359.0M | 955.3M | 2.9B | 2.9B | 2.5B | 2.6B | |
Property Plant And Equipment Gross | 11.4M | 180.0M | 258.6M | 447.8M | 566.0M | 594.3M | |
Total Current Assets | 97.2M | 1.2B | 2.2B | 1.7B | 1.1B | 1.2B | |
Accumulated Other Comprehensive Income | (12.5M) | 7.0M | (1.4M) | (6.4M) | 2.7M | 2.9M | |
Net Receivables | 7.5M | 262.0M | 455.0M | 82.4M | 297.2M | 312.1M | |
Non Current Liabilities Total | 333.2M | 633.2M | 538.1M | 432.8M | 937.1M | 984.0M | |
Intangible Assets | 6.5M | 5.6M | 5.7M | 4.8M | 4.3M | 4.1M | |
Short Long Term Debt Total | 321.9M | 322.0M | 454.0M | 549.8M | 229.1M | 140.8M | |
Common Stock Total Equity | 3.8M | 324K | 714K | 764K | 878.6K | 1.3M | |
Short Term Debt | 1.3M | 322.0M | 130.5M | 352.1M | 5.1M | 4.9M | |
Common Stock | 324K | 714K | 764K | 868K | 1.4M | 1.3M | |
Long Term Debt | 320.6M | 322.0M | 323.5M | 166.5M | 168.0M | 114.6M | |
Inventory | (83.0M) | (166.7M) | (2.0B) | 36.7M | 41.7M | 43.8M | |
Property Plant Equipment | 11.4M | 180.0M | 228.7M | 400.5M | 460.6M | 483.6M | |
Other Liab | 2.6M | 3.4M | 175.5M | 185.0M | 212.8M | 223.4M | |
Current Deferred Revenue | 1.7M | 273.2M | 1.4B | 370.1M | 241.3M | 140.2M | |
Other Assets | 1.1M | 5.4M | 16.6M | 28.5M | (57.9M) | (55.0M) | |
Good Will | 51.2M | 135.4M | 131.5M | 126.3M | 127.5M | 133.8M | |
Short Term Investments | 22.0M | 0.0 | 157.6M | 10.4M | 12.0M | 11.4M | |
Net Tangible Assets | (242.8M) | 486.1M | (487.9M) | (760.4M) | (684.4M) | (650.1M) | |
Retained Earnings Total Equity | (1.3B) | (1.4B) | (1.9B) | (3.6B) | (3.3B) | (3.1B) | |
Long Term Debt Total | 319.2M | 320.6M | 322.0M | 323.5M | 372.0M | 234.9M | |
Capital Surpluse | 1.1B | 1.3B | 2.5B | 3.4B | 3.9B | 4.0B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.